EE88 Cost-Effectiveness of Apixaban Compared to Warfarin, Dabigatran and Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation: Results for High-Risk Patient Subgroups Based on the Aristophanes Real-World Evidence Study
Abstract
Authors
C Spalding B Mountford S. Czarnota-Bojarski T Strakosch R Subash